cagrilintide semaglutide combination trial weight loss New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Weight Loss Efficacy of Cagrilintide

Doctors should watch for these and teach patients to recognize severe reactions

Tendonsa source of major concern in competitive and recreational athletes

Much of Noopept cognitive effect may be mediated through its metabolite cycloprolylglycine (cPG), which concentrates preferentially in the hippocampus and has been shown to reduce hippocampal cell death, increase BDNF mRNA, and modulate inflammatory cytokine expression

The diverse clinical picture of male PRLomas, varies from asymptomatic (18), through a predominance of hypogonadotropic hypogonadism (HH) features (7, 9, 12, 13, 15, 1723), to invasive tumors with extrasellar extension (16, 24)